At the moment, there are no pharmacological treatments for Autism Spectrum Disorder (ASD) core features. There is a growing interest in non-pharmacological interventions for ASD, such as neuromodulation with brain photobiomodulation 🧠
Dr Pallanti Stefano, a Stanford University Professor and Director of Istituto di Neuroscienze, Florence, Italy, led an independent retrospective study with the Vielight Neuro (Gamma and Alpha) on children with ASD.
Data was reported and analyzed from 21 patients (13 males, 8 females) with an average age of 9.1 (range 5–15), who received six months of transcranial-intranasal photobiomodulation at home using two protocols (Alpha and Gamma).
They were evaluated at baseline, after three and six months of treatment using the Childhood Autism Rating Scale (CARS), the Home Situation Questionnaire-ASD (HSQ-ASD), the Autism Parenting Stress Index (APSI), the Montefiore Einstein Rigidity Scale–Revised (MERS–R), the Pittsburgh Sleep Quality Index (PSQI) and the SDAG, to evaluate attention.
Findings show that after 6 months, transcranial-intranasal brain PBM was associated with:
- reduction in ASD severity, as shown by a decrease in CARS scores (p < 0.001).
- reduction in noncompliant behavior
- reduction in parental stress
- reduction in behavioral and cognitive rigidity
- improvement in attentional functions and in sleep quality.
We are thankful for Dr. Pallanti’s independent work with our technology and its contributions to advancing the field of brain photobiomodulation 👨🔬
Dr. Pallanti’s autism study: https://www.mdpi.com/2227-9067/9/5/755/htm
